A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Back to Search
Print
Bookmark Trial

NCT01342211

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Orange County Research Center
Tustin, California, 92780, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypercholesterolemia, Dyslipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- On a stable daily dose of atorvastatin, rosuvastatin or simvastatin.

- Lipids meet the following criteria at screening and prior to dosing: Fasting LDL-C greater than 100 mg/dL and fasting TG less than 400 mg/dL

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History of a cardiovascular or cerebrovascular event or procedure during the past
year.


- Poorly controlled type 1 or type 2 diabetes mellitus.


- Poorly controlled hypertension.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Hypercholesterolemia, DyslipidemiaA Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
NCT01350141
  1. Birmingham, Alabama
  2. Garden Grove, California
  3. Garden Grove, California
  4. Long Beach, California
  5. Wildomar, California
  6. Clearwater, Florida
  7. DeLand, Florida
  8. Miami, Florida
  9. Orlando, Florida
  10. Atlanta, Georgia
  11. Overland Park, Kansas
  12. Overland Park, Kansas
  13. Overland Park, Kansas
  14. Kansas City, Missouri
  15. Kansas City, Missouri
  16. Saint Louis, Missouri
  17. Raleigh, North Carolina
  18. Raleigh, North Carolina
  19. Oklahoma City, Oklahoma
  20. Oklahoma City, Oklahoma
  21. Oklahoma City, Oklahoma
  22. Oklahoma City, Oklahoma
  23. Duncansville, Pennsylvania
  24. Greer, South Carolina
  25. Kingsport, Tennessee
  26. Houston, Texas
  27. Tomball, Texas
  28. Orem, Utah
  29. Richmond, Virginia
  30. Kelowna, British Columbia
  31. Chicoutimi, Quebec
  32. Laval, Quebec
  33. Montreal, Quebec
  34. Sherbrooke, Quebec
  35. Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hypercholesterolemia, DyslipidemiaA Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
NCT01342211
  1. Tustin, California
  2. Walnut Creek, California
  3. Clearwater, Florida
  4. DeLand, Florida
  5. Doral, Florida
  6. Jacksonville, Florida
  7. Miami, Florida
  8. Woodstock, Georgia
  9. Woodstock, Georgia
  10. Overland Park, Kansas
  11. Wichita, Kansas
  12. Louisville, Kentucky
  13. Madisonville, Kentucky
  14. Auburn, Maine
  15. North Dartmouth, Massachusetts
  16. Kansas City, Missouri
  17. Kansas City, Missouri
  18. Kansas City, Missouri
  19. Saint Louis, Missouri
  20. Albuquerque, New Mexico
  21. Raleigh, North Carolina
  22. Salisbury, North Carolina
  23. Oklahoma City, Oklahoma
  24. Oklahoma City, Oklahoma
  25. Oklahoma City, Oklahoma
  26. Oklahoma City, Oklahoma
  27. Duncansville, Pennsylvania
  28. Philadelphia, Pennsylvania
  29. Philadelphia, Pennsylvania
  30. Spartanburg, South Carolina
  31. Knoxville, Tennessee
  32. Knoxville, Tennessee
  33. Houston, Texas
  34. San Antonio, Texas
  35. San Antonio, Texas
  36. San Antonio, Texas
  37. Norfolk, Virginia
  38. Richmond, Virginia
  39. Kelowna, British Columbia
  40. Chicoutimi, Quebec
  41. Laval, Quebec
  42. Montreal, Quebec
  43. Sherbrooke, Quebec
  44. Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hypercholesterolemia, DyslipidemiaPharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
NCT01163851
  1. Peoria, Arizona
  2. Phoenix, Arizona
  3. Phoenix, Arizona
  4. Overland Park, Kansas
  5. Overland Park, Kansas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hypercholesterolemia, DyslipidemiaMultiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
NCT01163838
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
Official Title  ICMJE A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin.
Brief Summary This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Hypercholesterolemia
  • Dyslipidemia
Intervention  ICMJE
  • Biological: Placebo
    Intravenous placebo monthly during treatment phase.
  • Drug: Statin
    Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
  • Biological: PF-04950615 (RN316)
    Intravenous 10mg/mL based on weight monthly during treatment phase.
  • Drug: Satin
    Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Study Arms  ICMJE
  • Placebo Comparator: Treatment A
    Interventions:
    • Biological: Placebo
    • Drug: Statin
  • Experimental: Treatment B
    Interventions:
    • Biological: PF-04950615 (RN316)
    • Drug: Statin
  • Experimental: Treatment C
    Interventions:
    • Biological: PF-04950615 (RN316)
    • Drug: Statin
  • Experimental: Treatment D
    Interventions:
    • Biological: PF-04950615 (RN316)
    • Drug: Satin
  • Experimental: Treatment E
    Interventions:
    • Biological: PF-04950615 (RN316)
    • Drug: Statin
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 16, 2013)		93
Original Estimated Enrollment  ICMJE
 (submitted: April 25, 2011)		90
Actual Study Completion Date  ICMJE June 2012
Actual Primary Completion Date February 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • On a stable daily dose of atorvastatin, rosuvastatin or simvastatin.
  • Lipids meet the following criteria at screening and prior to dosing: Fasting LDL-C greater than 100 mg/dL and fasting TG less than 400 mg/dL

Exclusion Criteria:

  • History of a cardiovascular or cerebrovascular event or procedure during the past year.
  • Poorly controlled type 1 or type 2 diabetes mellitus.
  • Poorly controlled hypertension.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01342211
Other Study ID Numbers  ICMJE B1481005
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP